High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...
Fuente : http://www.alphagalileo.org/ViewItem.aspx?ItemId=1...